Loading
A Guangzhou company making DNA methylation tests in blood and urine, which announced a six-cancer blood test, Aurora, in 2020.
AnchorDx Medical, of Guangzhou, with a US entity in Fremont, California, according to its authors' affiliations, has published methylation assays for lung, bladder, kidney and colorectal cancer and a two-cancer colorectal and gastric study. It announced Aurora, a methylation blood test for six cancers, in June 2020.
A methylation blood test for six common cancers announced by AnchorDx of Guangzhou in 2020 at a target cost of about $100; whether it reached the market could not be confirmed.
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/